New combo shows promise for Hard-to-Treat lymphoma
NCT ID NCT02086175
First seen Apr 09, 2026 · Last updated Apr 25, 2026 · Updated 3 times
Summary
This study tested a combination of two drugs, Imprime PGG and Rituximab, in 25 people with a type of blood cancer called indolent non-Hodgkin lymphoma that had come back or not responded to prior treatment. The goal was to see how many patients had their tumors shrink or disappear. The study is complete, and results help guide future treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY INDOLENT B CELL NON-HODGKIN LYMPHOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.